Good day, everyone, and welcome to the Insulet Corporation 2020 Annual Meeting of Stockholders. I would now like to turn the conference call over to Shacey Petrovic, President and Chief Executive Officer. Please go ahead.
Thank you, and good morning, everyone. Welcome to the 2020 Annual Meeting of Insulet Corporation. I am Shacey Petrovic, President and Chief Executive Officer of Insulet, and I will be presiding over the meeting. Due to the COVID-19 pandemic, in order to ensure the health and safety of our shareholders, our employees, and our board of directors, this annual meeting is being conducted virtually via live webcast. The last few months have posed extraordinary challenges for countries and communities around the world as we've grappled with the impact of COVID-19.
Our hearts go out to those whose health has been affected, and our gratitude goes out to the many medical professionals and first responders on the front lines. We also hope that all of you joining us on today's call are staying safe and healthy. As a company committed to improving the lives of people with diabetes, the safety and well-being of our Insulet employees, the communities, and patients we serve have been our top priorities as we navigate these difficult circumstances. In March, we transitioned to remote work arrangements for the vast majority of our employees, in line with guidance issued by the WHO, the CDC, local governments, and local health authorities.
For those employees performing critical on-site functions, we significantly enhanced safety procedures to include social distancing, PPE protocols, frequent deep cleaning of our facilities, and temperature monitoring. I am pleased to report that this transition has been essentially seamless, and on behalf of our leadership team, I'd like to express our sincere gratitude to the employees who are continuing to work on-site to ensure we can provide uninterrupted supply of Omnipod to our customers.
I am incredibly proud of our global team's resilience and compassion in the face of this challenge. While balancing many other demands, such as working from home, caring for children, and keeping their families and friends healthy, our dedicated employees have never lost focus on our mission. Our Insulet team is what makes us such a great company, and I want to thank each and every one of our employees across the globe. I'd also like to thank our many supply chain partners for supporting our ability to build excess capacity and redundancy to ensure we can serve our customers without interruption and without delay.
I would now like to introduce the other members of our board of directors. They bring diverse perspectives and a breadth of experience. They are leaders in business, healthcare, and technology, and each director brings deep expertise and skills to his or her role. Joining us virtually today are Sally Crawford, Dr. John Fallon, Dr. Jim Hollingshead, Dr. Jessica Hopfield, David Lemoine, Mike Minogue, Corinne Nevinny, and Tim Scannell. In addition, with me here today is Jack Kapples, our General Counsel and Secretary. We also have on the line representatives from Grant Thornton, our independent auditors.
The agenda for today's meeting and the rules of order are available in the meeting materials section of the virtual meeting website. There you will also find links to our 2020 proxy statement and 2019 annual report. We do not expect any technical difficulties today, but in the event we lose our webcast connection or otherwise experience issues, please wait at least 10 minutes for resolution and refer to the virtual meeting website for updates. The Question and Answer portion of our meeting will be held after all proposals have been introduced.
If you wish to submit a question, please type it into the Ask a Question field and click Submit on the meeting website. I now call the meeting to order. I have been advised by the secretary that proper notice of this meeting was given, a quorum is present, the meeting is duly constituted, and that the business of the meeting may proceed. It is 10:04 . The polls are now open, and we will proceed with the formal business of the meeting. If you have already submitted your proxy and you do not intend to change your vote, you do not need to vote today. Your shares will be voted in accordance with the directions you provided in your proxy.
If you are eligible to vote and have not submitted your proxy, or if you want to change your vote, you may vote today by clicking Vote Here on the meeting website. The first item of business is the Election of Directors. As described in the proxy statement, we will be voting on three nominees: Sally Crawford, Michael Minogue, and Corinne Nevinny to serve as Class I Directors for a term of three years. The board recommends a vote for each of the nominees.
The second item of business is the approval on a non-binding advisory basis of a resolution regarding the compensation of the named executive officers, as described in the Compensation Discussion and Analysis section of the proxy statement. Although this is an advisory vote and the results of the vote will not be binding on the board or the company, the board understands the importance of receiving shareholder feedback on executive compensation. The board recommends a vote for this proposal.
The third and final item of business is the ratification of the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2020, and the board recommends a vote for this proposal. Anyone who has not yet voted, please do so now as the polls will be closing shortly. It is now 10:06 , and the polls for each matter to be voted on at this meeting are now closed. No additional proxies or votes, and no changes or revocations will be accepted.
That concludes our official business, and I declare the formal business of the meeting closed, and the meeting is now adjourned. While we wait for the preliminary voting results, I want to update you on the state of our company. Insulet experienced tremendous growth and success in 2019, setting the stage for strong financial and operational excellence in 2020, despite the current external environment. The foundation we've built is the result of several years of strategic discipline, and it will allow us to grow and evolve while staying true to our mission to improve the lives of people with diabetes.
We continue to focus on delivering consumer-focused innovation, ensuring the best possible global customer experience, expanding our global footprint, and driving operational excellence. As we look ahead, we are confident that the execution of our strategy is driving sustainable long-term growth and value creation. Diabetes is a growing health crisis, and the number of diagnosed cases continues to increase globally each year. There is significant unmet need in the underserved Type 1 and Type 2 diabetes market that Insulet is uniquely qualified to address with our innovative technologies.
As the current COVID-19 pandemic began to unfold a few months ago, we were well situated with healthy inventory levels, a strong balance sheet, robust global manufacturing operations, and plans to capitalize on our growth prospects. Our first quarter performance in 2020 is a testament to the resilience of our business model and to our team's execution. We also made continued progress on our strategic imperatives. We achieved first quarter revenue of almost $200 million, representing a 25% increase year- over- year, driven by 34% revenue growth in our total diabetes product line.
Even though the current environment is unusually challenging, we are confident that our 2019 and Q1 2020 momentum will provide a great deal of insulation. Assuming market dynamics normalize early next year, we expect to achieve our $1 billion revenue goal for 2021. Last year, we launched our Omnipod DASH system in United States, and in December, we released Omnipod DASH in selected European countries. We continue to grow the number of Omnipod DASH users thanks to its simple, easy-to-use, intuitive design. Omnipod DASH is the first FDA-cleared insulin delivery system controlled by a consumer Android device.
The device communicates via Bluetooth to the pod and via Bluetooth to the cloud, with mobile apps that provide users with the freedom and flexibility to discreetly manage their diabetes so they can enjoy more of what they love to do. In the United States, Omnipod DASH is available through the pharmacy channel, which offers the convenience of the pay-as-you-go model and provides favorable and predictable out-of-pocket costs. With Omnipod in the pharmacy, we have eliminated the upfront cost of the system, and the payer or the patient is simply paying for pods as the benefit of the technology is being realized.
Along with our innovative business model, we are also focused on innovating our product platform as we continue to develop our next-generation product, Omnipod, powered by Horizon. Omnipod Horizon is the first tubeless, personal smartphone-controlled, automated insulin delivery system, and we're highly confident it will be a game changer for people living with diabetes. We have received overwhelmingly positive feedback from participants in our clinical trial, and we expect to bring Omnipod Horizon to the U.S. market in the first half of 2021.
In addition to our progress with Omnipod Horizon, we have continued to advance our collaborations with Dexcom, Abbott, and Tidepool to bring advanced systems to the market on various platforms through interoperability. Over the coming years, we expect that these partnerships will bring exciting new products to market that will deliver reduced- burden and improved outcomes for people living with insulin-dependent diabetes. Turning to our manufacturing innovation and global operational excellence, just one year ago, we began production on our first highly automated manufacturing line in the United States.
We have been building redundancy with our U.S. manufacturing capabilities to supplement our capacity in China, as well as create redundancy throughout our entire global supply chain. The importance of this effort was highlighted as we successfully maintained production and supply chain continuity in the face of COVID-19, first in China and then in the United States. Our entire team rose to the challenge to ensure that we are producing at planned product levels while ensuring the safety and well-being of our global employees. We are laser-focused on making sure our customers receive uninterrupted access to Omnipod.
We have an amazing team of people around the world who are committed to our mission of improving the lives of people with diabetes. Our goal is to bring the simplest, most consumer-friendly technology to market. Our business model innovation is designed to ensure cost-effective access to the broadest population of users across the globe. And our investment in operational excellence will help to ensure supply chain resiliency, world-class manufacturing capabilities, and industry-leading gross margins. Although we are still in the early innings, we are well on our way to delivering our promise to our customers and continued value creation for our shareholders.
Will the secretary now please report on the preliminary voting results?
Thank you, Shacey. The preliminary voting results are based on tabulations received from Broadridge Financial Services and our Inspector of Elections and are as follows. Proposal 1, the three Director nominees named in the proxy statement have been elected, with each nominee having received at least 96% in favor of reelection. Proposal 2, the advisory vote on the compensation of the company's named executive officers was approved, with 98% of the votes cast for this proposal.
Proposal 3, the ratification of the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2020, was approved, with 99% of the votes cast for this proposal. The final voting results will be set forth in the report of the Inspector of Elections and will be disclosed within four business days of the meeting on a Form 8-K to be filed with the Securities and Exchange Commission.
Thank you, Jack. With that, we will now move to the Question-and-Answer portion of the meeting. If there are questions, over the next 10 to 15 minutes, we will answer as many as we can. If we receive substantially similar questions, we will group those questions together and provide a single response to avoid repetition. Answers to any questions that were not addressed during the meeting will be published following the meeting in the corporate governance section of our website, www.insulet.com.
Shacey, at this time, there are no questions pending.
Thank you, Jack. This concludes our meeting. Thank you all for attending and for your continued support of Insulet.